Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014

David Nathanson, Ugne Sabale (), Jan W. Eriksson, Thomas Nyström, Anna Norhammar, Urban Olsson and Johan Bodegård
Additional contact information
David Nathanson: Karolinska Institutet, Södersjukhuset
Ugne Sabale: Astra Zeneca Nordic-Baltic
Jan W. Eriksson: Uppsala University
Thomas Nyström: Karolinska Institutet, Södersjukhuset
Anna Norhammar: Karolinska University Hospital Solna
Urban Olsson: Statisticon AB
Johan Bodegård: AstraZeneca Nordic-Baltic

PharmacoEconomics - Open, 2018, vol. 2, issue 4, No 6, 393-402

Abstract: Abstract Objective The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006–2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs). Methods In- and outpatient healthcare resource use and costs were extracted from mandatory national registries: the Cause of Death Register; the National Patient Register; and the Prescribed Drug Register. Primary care data were estimated based on an observational study including patients from 84 primary care centers in Sweden. Numbers of any cause inpatient, outpatient, and primary care contacts were extracted and direct healthcare costs were estimated. Results During 2006–2014, the number of inpatient and primary care contacts increased by approximately 70% (from 45,559 to 78,245 and from 4.9 to 8.8 million, respectively) and outpatient care contacts almost doubled (from 105,653 to 209,417). Mean annual per patient costs increased by 13%, reaching €4594. Total healthcare costs increased from €835 million to €1.684 billion. Inpatient care costs constituted 47% of total costs in 2014 (€783 million), primary care accounted for 24% (€405 million), outpatient care 18% (€303 million), non-GLD medications 6% (€109 million), and GLDs 5% (€84 million). Cardiovascular diseases (CVDs) were the most costly disease group in inpatient care (26%), whereas managing unspecified factors influencing health and T2D-associated diseases were the most costly in outpatient care (16 and 11%, respectively). Conclusions The healthcare costs of the GLD-treated T2D population doubled during 2006–2014, mostly driven by the increasing size of this population, of which inpatient care accounted for 47%. GLDs constituted the smallest share of costs. CVD was the most resource-requiring disease group.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0063-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:4:d:10.1007_s41669-017-0063-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0063-y

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().